- Home
- DNTH vs ARQQ Comparison
DNTH vs ARQQ Comparison
Compare DNTH & ARQQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNTH
- ARQQ
- Stock Information
- Founded
- DNTH 2015
- ARQQ 2017
- Country
- DNTH United States
- ARQQ United Kingdom
- Employees
- DNTH N/A
- ARQQ N/A
- Industry
- DNTH Biotechnology: Pharmaceutical Preparations
- ARQQ Computer Software: Prepackaged Software
- Sector
- DNTH Health Care
- ARQQ Technology
- Exchange
- DNTH Nasdaq
- ARQQ Nasdaq
- Market Cap
- DNTH 568.6M
- ARQQ 598.3M
- IPO Year
- DNTH N/A
- ARQQ N/A
- Fundamental
- Price
- DNTH $18.85
- ARQQ $35.00
- Analyst Decision
- DNTH Strong Buy
- ARQQ Strong Buy
- Analyst Count
- DNTH 8
- ARQQ 1
- Target Price
- DNTH $53.00
- ARQQ $52.00
- AVG Volume (30 Days)
- DNTH 315.6K
- ARQQ 1.2M
- Earning Date
- DNTH 08-07-2025
- ARQQ 05-22-2025
- Dividend Yield
- DNTH N/A
- ARQQ N/A
- EPS Growth
- DNTH N/A
- ARQQ N/A
- EPS
- DNTH N/A
- ARQQ 0.48
- Revenue
- DNTH $6,524,000.00
- ARQQ $241,000.00
- Revenue This Year
- DNTH N/A
- ARQQ $1,818.77
- Revenue Next Year
- DNTH N/A
- ARQQ N/A
- P/E Ratio
- DNTH N/A
- ARQQ $72.42
- Revenue Growth
- DNTH 102.36
- ARQQ N/A
- 52 Week Low
- DNTH $13.37
- ARQQ $3.72
- 52 Week High
- DNTH $32.27
- ARQQ $52.79
- Technical
- Relative Strength Index (RSI)
- DNTH 54.07
- ARQQ 57.65
- Support Level
- DNTH $17.27
- ARQQ $32.80
- Resistance Level
- DNTH $19.46
- ARQQ $43.50
- Average True Range (ATR)
- DNTH 1.07
- ARQQ 4.26
- MACD
- DNTH 0.15
- ARQQ -0.38
- Stochastic Oscillator
- DNTH 76.74
- ARQQ 54.62
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
About ARQQ Arqit Quantum Inc.
Arqit Quantum Inc is a cybersecurity company that has pioneered a symmetric key agreement technology that makes the communications links of any networked device or data at rest secure against current and future forms of cyber attack - even an attack from a quantum computer. The company delivers its symmetric key agreement technology via its product SKA-Platform. The firm operates in one segment that is, the provision of cybersecurity services. The company operates and generates its revenue from UK.